![]() |
市場調查報告書
商品編碼
2026865
水凝膠敷料市場預測至2034年—按產品、材料、應用、最終用戶和地區分類的全球分析Hydrogel Dressing Market Forecasts to 2034 - Global Analysis By Product, Material, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球水凝膠敷料市場規模將達到 11.023 億美元,並在預測期內以 6.2% 的複合年成長率成長,到 2034 年將達到 17.836 億美元。
水凝膠敷料是一種高含水量的醫用材料,旨在促進創傷治療並維持傷口濕潤環境。水凝膠敷料具有多種優點,包括清涼效果、緩解疼痛和防止傷口乾燥。它們可有效治療各種類型的傷口,例如燒燙傷、潰瘍和擦傷。
根據國際糖尿病聯盟(IDF)的數據,截至 2020 年 2 月,估計有 4.63 億人患有糖尿病。
日益增強的意識
隨著人們越來越認知到水凝膠敷料能夠促進組織修復和細胞增殖,它們已被納入標準創傷護理方案。水凝膠敷料透過包括網路和醫療專業人員在內的各種管道傳播,使人們能夠更好地維護自身健康。此外,醫療專業人員也越來越意識到保持傷口濕潤癒合環境的重要性,並且能夠就傷口管理做出明智的決策。
高成本
開發含有新型添加劑和特殊聚合物的複雜水凝膠配方需要最先進的材料和技術,導致生產成本高。此外,醫院、診所和醫護人員在將水凝膠敷料納入標準創傷護理方案時,可能會面臨經濟挑戰。這種經濟負擔可能會影響患者的依從性,並促使他們選擇更經濟的創傷護理方案,這可能會阻礙市場擴張。
技術進步
技術進步正在提升敷料在創造和維持最佳創傷治療環境方面的有效性,最終加速復原進程。這些產品整合了感測器和指示器,可監測各種傷口參數,例如pH值、溫度和感染指標。材料科學與技術(例如奈米技術)的持續創新正在推動性能更優異的精密水凝膠配方的研發,從而促進市場擴張。
缺乏意識
認知不足會導致不恰當的創傷護理操作和重要醫療器材的誤用。相當一部分醫護人員和患者可能不完全了解水凝膠敷料的用途和益處。此外,認知不足還會導致需求疲軟,阻礙水凝膠敷料進入市場及其在常規創傷護理中的應用,進而抑制市場成長。
新冠疫情的影響
新冠疫情對水凝膠敷料市場造成了多方面的負面影響。供應鏈中斷和物流挑戰影響了包括水凝膠敷料在內的醫療產品的供應。生產和分銷延遲,以及某些醫療產品需求的增加,都造成了不確定性。此外,醫院在管理非新冠患者方面面臨許多挑戰,這影響了先進創傷護理解決方案的常規使用。疫情相關的景氣衰退加劇了醫療機構的預算壓力,進而阻礙了市場成長。
在預測期內,非晶質水凝膠部分預計將是最大的部分。
非晶質水凝膠敷料預計將佔據最大的市場佔有率。這類敷料由高水分、無固定形狀的凝膠組成,因此用途廣泛,適用於各種類型的傷口。它們易於塗抹和溫和移除,是部分燒傷、擦傷和供皮區處理的理想選擇。這類敷料具有清涼舒緩的效果,可減輕患者在換藥過程中的疼痛和不適。此外,這類敷料在維持傷口濕潤環境方面表現出色,為促進傷口癒合創造了最佳條件,並顯著推動了該細分市場的成長。
在預測期內,靜脈潰瘍部分的複合年成長率預計將最高。
由於能夠滿足與慢性靜脈功能不全相關的特定治療需求,預計靜脈性腿部潰瘍細分市場在預測期內將呈現最高的複合年成長率。這是因為水凝膠敷料在治療此類潰瘍方面發揮著至關重要的作用,它能創造最佳的濕潤環境,促進傷口癒合,包括常發生於下肢的循環障礙引起的傷口。隨著醫療專業人員日益認知到水凝膠敷料在治療靜脈性腿部潰瘍方面的有效性,它有助於改善患者的治療效果和生活品質,從而推動該細分市場的擴張。
在預測期內,北美佔據了最大的市場佔有率,這主要得益於其強大的醫療保健基礎設施、技術創新以及積極主動的創傷護理方法。該地區致力於透過治療糖尿病和肥胖症等慢性疾病來改善患者的治療效果和提高護理品質。加拿大、墨西哥和美國等地區對水凝膠配方的持續研發正在推動該地區的成長,確保這些敷料能夠滿足醫療專業人員和患者不斷變化的需求。
預計歐洲在預測期內將實現最高的複合年成長率。研發工作正推動水凝膠配方的持續創新,提升其療效並擴大其應用範圍。歐洲的法規結構確保了醫療產品的安全性和有效性,並增強了醫護人員和病患的信心。 3M、強生服務公司、美Medtronic和史密斯醫療等領導企業在推動技術創新和實證醫學方面發揮著至關重要的作用,進而促進了該地區的進一步發展。
According to Stratistics MRC, the Global Hydrogel Dressing Market is accounted for $1102.3 million in 2026 and is expected to reach $1783.6 million by 2034 growing at a CAGR of 6.2% during the forecast period. A hydrogel dressing is a medical material with a high water content designed to promote wound healing and maintain a moist environment. Hydrogel dressings provide several benefits, including cooling effects, pain relief, and preventing wound dehydration. They are effective in managing various types of wounds, such as burns, ulcers, and abrasions.
According to International Diabetes Federation (IDF), as of February 2020, 463 million people were calculated to be living with diabetes.
Increasing awareness
The awareness that hydrogel dressings promote optimal conditions for tissue repair and cell proliferation has led to their integration into standard wound care protocols. These are promoted through various channels, including the internet and healthcare professionals, and empower individuals to advocate for their well-being. Furthermore, healthcare providers are now better equipped to make informed decisions about wound management, recognizing the significance of maintaining a moist healing environment.
High cost
The development of complex hydrogel formulations, which include novel additives and specialized polymers, involves high production costs as they are made using cutting-edge materials and technologies. In addition, hospitals, clinics, and healthcare providers may face financial challenges when incorporating hydrogel dressings into their standard wound care protocols. This financial burden may influence patient compliance and preference for more economical wound care options, hampering this market expansion.
Technological advancements
The technological enhancements contribute to the dressings' efficacy in creating and maintaining an optimal environment for wound healing, ultimately accelerating the recovery process. These are equipped with sensors or indicators that monitor various wound parameters, such as pH levels, temperature, and infection markers. Continuous innovation in materials science technologies such as nanotechnology has led to the development of highly sophisticated hydrogel formulations with enhanced properties, which are driving this market expansion.
Lack of awareness
A lack of awareness may result in inadequate wound care procedures and inadequate use of a significant medical tool. It's possible that a sizable percentage of medical professionals and patients are not fully aware of the uses and advantages of hydrogel dressings. Additionally, low awareness can lead to low demand, which prevents hydrogel dressings from entering the market and from being easily incorporated into regular wound care routines, which is hindering this market's growth.
Covid-19 Impact
The COVID-19 pandemic has had several negative impacts on the hydrogel dressing market. Supply chain disruptions and logistic challenges affected the availability of medical products, including hydrogel dressings. Manufacturing and distribution delays, as well as increased demand for certain healthcare products, contributed to uncertainties. In addition, hospitals faced challenges in managing non-COVID patients, impacting the regular utilization of advanced wound care solutions. The economic downturn associated with the pandemic resulted in budget constraints for healthcare facilities, thereby impeding this market size.
The amorphous hydrogel segment is expected to be the largest during the forecast period
The amorphous hydrogel segment is estimated to hold the largest share. These are composed of a high-water-content gel without a defined shape and are versatile solutions for various wound types. This is often preferred for managing partial-thickness burns, abrasions, and donor sites due to its ease of application and gentle removal, which offer cooling and soothing effects, reducing pain and discomfort for patients during dressing changes. Furthermore, these dressings excel at maintaining a moist wound environment, promoting optimal conditions for accelerated healing, thereby significantly driving this segment's growth.
The venous leg ulcer segment is expected to have the highest CAGR during the forecast period
The venous leg ulcer segment is anticipated to have highest CAGR during the forecast period, due to its ability to address a specific therapeutic need associated with chronic venous insufficiency. This plays a major role in managing these ulcers by creating an optimally moist environment that facilitates the healing process, including wounds caused by impaired blood circulation, often occurring in the lower extremities. As healthcare professionals increasingly recognize the efficacy of hydrogel dressings in managing venous leg ulcers, it is contributing to improved outcomes and quality of life for patients, which is boosting this segment expansion.
North America commanded the largest market share during the extrapolated period owing to a robust healthcare infrastructure, technological innovation, and a proactive approach to advanced wound care. They focused on patient outcomes and quality of care by treating chronic conditions, including diabetes and obesity. Regions such as Canada, Mexico, and the United States lead to continuous research and development in hydrogel formulations, ensuring that these dressings meet the evolving needs of healthcare providers and patients, which is boosting this region's growth.
Europe is expected to witness highest CAGR over the projection period. Research and development contribute to the continuous innovation of hydrogel formulations, enhancing their effectiveness and expanding their applications. Regulatory frameworks in Europe ensure the safety and efficacy of medical products, instilling confidence in healthcare professionals and patients alike. Key players, including 3M Company, Johnson & Johnson Services, Inc., Medtronic plc, and Smith & Nephew plc, play a major role in contributing technological innovations and evidence-based medicine, which further propel this region's expansion.
Key players in the market
Some of the key players in the Hydrogel Dressing Market include 3M Company, Axelgaard Manufacturing Co Ltd, Convatec Group plc, B Braun Melsungen AG (B. Braun Holding GmbH & Co. KG), Integra LifeSciences, Hollister Incorporated, Lohmann & Rauscher GmbH & Co. KG, McKesson Corporation, Medline Industries LP, Procyon Corporation, Smith & Nephew plcand Amerx health care corp.
In August 2023, 3M announced that it has reached an agreement with the court-appointed negotiating plaintiffs' counsel to resolve the Combat Arms Earplug litigation against Aearo Technologies (Aearo) and 3M.
In September 2023, Procyon Advisors LLC had acquired a new position in the shares of ON Semiconductor Corporation during the second quarter.
In July 2023, Convatec Group Plc announced its collaboration with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the world's smallest durable automated insulin delivery system that has now been FDA 510(k) cleared3.